Three charts highlight the dangerous divergence in prospects across advanced economies and many emerging markets and developing countries.
[1/] Divergences in vaccine access.
Congratulations to the @nytimes on the Public Service #Pulitzer Award!
The need for real-time, reliable data has never been more pressing and the pandemic has shown how critical independent quality #journalism is to better decision making and public trust.
How much vaccine will be produced this year?
The third article of the series created in partnership with @SimonEvenett highlights the critical importance of globally distributing the huge number of vaccines likely to be produced this year. #CovidVaccine
https://t.co/jF21WA7vJh
@Swen_2017 Hi - thanks for flagging. Our team has been on a call w. the journalist and clearly explained our methodology which he chooses to ignore. We stand by our numbers and conclusions and even the EU has conceded this. He clearly has an agenda. For more contact: [email protected]
.@TheLancetInfDis reports on the hope for #Europe to reach #immunisation by the end of Summer including @Airfinity insights predicting some countries reaching that level of protection only later this year.
https://t.co/Z7Jjdv1zij
Our #COVID19 vaccine insight of the day is our view on total doses produced and the number of doses that have actually been exported across countries/regions.
@Swen_2017@BBCr4today Thanks and good to be on. Short interview, but we do take those factors and many more including risk adjusted production into account. Much will depend on 1-dose J&J scale up. Some more data avail on https://t.co/JQeCBnKUrL
Thank you for the interview @rhysblakely@thetimes. Great to discuss our forecast on the effect of UK’s #covid19vaccine approach.
https://t.co/JZKQO48pmW
The enormous return on investment reflects the immense scale of the damage caused by the pandemic, @rasbech told @thetimes. “Vaccine production costs billions. But you get benefits in the order of trillions, so it’s worth doing.” 7/7
Read the full story:
https://t.co/csqvKylVS4
The vaccine market is being transformed by COVID-19. Airfinity data predicts vaccine sales of @Novavax and @moderna_tx overtakes 3 of the largest existing players. https://t.co/MpTB1d8cqB
The biggest surprise of the vaccine delays to me was that it caught so many by surprise. But @TimHarford explains well why even that shouldn't be a surprise.
Why does so much from vaccines to our home work get delayed? @TimHarford makes some astute observations on the "planning fallacy" here citing @rasbech . Valuable insights for anyone planning ahead during a pandemic. https://t.co/Ekzi8KjubA